4. TELADOC
Teladoc Health, Inc. is a
multinational telemedicine
and virtual healthcare
company headquartered in the
United States. Primary
services include telehealth,
medical opinions, AI and
analytics, telehealth devices
and licensable platform
services.
5. PFIZER
Pfizer Inc. is an American
multinational pharmaceutical
and biotechnology
corporation headquartered on
42nd Street in Manhattan, New
York City. The company was
established in 1849 in New
York by two German
entrepreneurs, Charles Pfizer
and his cousin Charles F.
Erhart.
6. MARKET CAPITALIZATION
The market capitalization sometimes referred as Market cap, is the value of a publicly listed company. In
most cases it can be easily calculated by multiplying the share price with the amount of outstanding
shares.
As of November 2022 Pfizer has a market cap of $276.52 Billion. This makes Pfizer the world's 28th most
valuable company by market cap according to our data. The market capitalization, commonly called
market cap, is the total market value of a publicly traded company's outstanding shares and is commonly
used to measure how much a company is worth.
As of November 2022 Teladoc Health has a market cap of $5.52 Billion. This makes Teladoc Health the
world's 2206th most valuable company by market cap according to our data. The market capitalization,
commonly called market cap, is the total market value of a publicly traded company's outstanding shares
and is commonly used to measure how much a company is worth.
7.
8. TELADOC
Q1
TELADOC'S FIRST-QUARTER REVENUE
REACHED $454 MILLION, JUMPING 151%
FROM $181 MILLION A YEAR AGO,
DRIVEN BY GROWTH IN SPECIALTY
OFFERINGS AND MULTI-PRODUCT
CONTRACTS.
DESPITE A HISTORICALLY WEAK FLU
SEASON, THE TELEHEALTH GIANT
DELIVERED 3.2 MILLION VIRTUAL VISITS
IN THE FIRST QUARTER OF 2021, UP 56%
COMPARED TO THE FIRST QUARTER IN
2020.
TELADOC ENDED THE QUARTER WITH
U.S. PAID MEMBERSHIP OF 51.5 MILLION
MEMBERS, AN INCREASE OF 20% OVER
THE PRIOR-YEAR QUARTER.
THE COMPANY'S QUARTERLY REVENUE
BEAT WALL STREET ESTIMATES OF $452
MILLION.
Pfizer
Q1
The company's first-quarter
revenue grew 77% to more than
$25 billion compared with the
same period last year, driven by
$13.2 billion in Covid vaccine
sales in the quarter and $1.5
billion in sales of its oral antiviral
treatment Paxlovid.
Pfizer booked net income of $7.8
billion, a 61% increase over the
first quarter of 2021. Adjusted
first-quarter earnings grew 72% to
$1.62 per share compared with
the same period last year.
9. TELADOC Q2
PFIZER'S REVENUE GREW BY 47% TO
$27.7 BILLION COMPARED TO THE
SECOND QUARTER LAST YEAR.
THE PHARMACEUTICAL COMPANY
BOOKED NET INCOME OF $9.9 BILLION, A
78% INCREASE OVER THE SAME PERIOD
DURING 2021.
PFIZER MAINTAINED ITS 2022 SALES
GUIDANCE FOR ITS COVID-19 VACCINE OF
$32 BILLION AND IS STILL EXPECTING $22
BILLION FOR ITS ORAL ANTIVIRAL
PAXLOVID.
PFIZER ALSO LARGELY REITERATED ITS
OVERALL 2022 REVENUE AND EARNINGS
GUIDANCE. PFIZER IS EXPECTING $98
BILLION TO $102 BILLION IN SALES THIS
YEAR AND EARNINGS PER SHARE OF
$6.30 TO $6.45. THE COMPANY RAISED
THE LOWER END OF ITS EARNINGS
GUIDANCE BY 5 CENTS.
PFIZER Q2
For Q2, total revenues of more than
$592 million were up nearly 18% over
the prior year period, and beat street
estimates by more than $5 million.
Over the past 6 months, the average
revenue estimate was down by about
6.7%, which translates to almost $40
million. Access fees revenue grew
20% to $518.7 million and visit fee
revenue grew 7% to $66.7 million.
Despite revenues rising sequentially
from period to period, EBITDA,
Adjusted EBITDA, and net loss per
share guidance have been getting
worse from quarter to quarter. The
company had almost $884 million in
cash at the end of Q2, but it also more
than $1.53 billion worth of convertible
debt.
10. TELADOC Q3
AFTER A ROUGH RIDE IN THE FIRST HALF OF
2022, TELADOC HAD SOME GOOD NEWS TO
REPORT THIS WEEK AS IT SLIGHTLY EXCEEDED
REVENUE EXPECTATIONS IN THE THIRD
QUARTER AND SAW ROBUST GROWTH IN ITS
DIRECT-TO-CONSUMER BUSINESS.
REVENUE DURING THE MOST RECENT
QUARTER ROSE 17% TO $611 MILLION
FROM $522 MILLION A YEAR AGO, SLIGHTLY
SURPASSING ANALYSTS' EXPECTATIONS OF
$609 MILLION.
ADJUSTED EARNINGS BEFORE INTEREST,
TAXES, DEPRECIATION AND AMORTIZATION
(EBITDA) DURING THE THIRD QUARTER CAME
TO $51.2 MILLION, COMPARED TO $67.4 MILLION
IN THE PRIOR YEAR'S QUARTER BUT STILL
ABOVE THE HIGH END OF THE COMPANY'S
GUIDANCE RANGE.
TELADOC NARROWED ITS LOSSES DURING
THE THIRD QUARTER. THE COMPANY
REPORTED A NET LOSS OF $73.5 MILLION, OR
45 CENTS A SHARE, COMPARED WITH A LOSS
OF $84.3 MILLION, OR 53 CENTS A SHARE, A
YEAR AGO.
PFIZER Q3
Pfizer’s third-quarter revenue was
$22.638 billion, compared with
$24.035 billion in the prior year’s
quarter, but above the FactSet
consensus of $21.072 billion.
Third-quarter 2022 revenues totaled
$22.6 billion, a decrease of $1.4
billion, or 6%, compared to the prior-
year quarter, reflecting an
operational decline of $441 million,
or 2%, as well as an unfavorable
impact of foreign exchange of $957
million, or 4%. Excluding
contributions from Paxlovid and
Comirnaty(1), company revenues
grew $213 million, or 2%,
operationally.
11. TELADOC PROFITABILITY RATIOS
The gross profit ratio shows the
proportion of profits generated by
the sale of products or services,
before selling and administrative
expenses. It is used to examine
the ability of a business to create
sellable products in a cost-
effective manner.
Gross profit ratio= (gross profit ÷
net sales) x100
12. TELADOC
PROFITABILITY
RATIO
Teladoc Health gross profit for the
twelve months ending September
30, 2022 was $1.593B, a 26.09%
increase year-over-year.
Teladoc Health cost of goods sold
for the twelve months ending
September 30, 2022 was $0.730B,
a 22.05% increase year-over-year.
Gross profit = net sales – COGS
1.593B=net sales – 0.730B
Net sales = 1.593+ 0.730
2.323B
Gross profit ratio = (1.593 ÷ 2.323)x100
68.5%
Average industry standard = 49.63%
13. TELADOC LEVERAGE RATIOS
A leverage ratio is any kind of financial ratio that indicates
the level of debt incurred by a business entity against
several other accounts in its balance sheet, income
statement, or cash flow statement.
Dept to equity ratio = (total liabilities ÷ share holders
equity )x100
Dept to equity ratio = (2.05 ÷ 6.05)x100
14. TELADOC LEVERAGE RATIO
Teladoc Health total liabilities for the quarter ending September 30,
2022 were $2.051B, a 23.2% increase year-over-year.
Teladoc Health share holder equity for the quarter ending
September 30, 2022 was $6.053B, a 62.14% decline year-over-year
Teladoc Health debt/equity for the three months ending September
30, 2022 was 0.25
Average industry standard 1.76
15. TELADOC LIQUIDITY RATIOS
Liquidity ratios are a measure of the
ability of a company to pay off its short-
term liabilities. Liquidity ratios
determine how quickly a company can
convert the assets and use them for
meeting the dues that arise. The higher
the ratio, the easier is the ability to clear
the debts and avoid
defaulting on payments.
Current Ratio % = (Current Assets /
Current Liabilities) * 100
16. TELADOC LIQUIDITY RATIO
Teladoc Health cash on hand for the quarter ending
September 30, 2022 was $0.900B, a 8.87% increase year-
over-year.
Teladoc health current liabilities amount to 411.40M.
Teladoc Health current ratio for the three months ending
September 30, 2022 was 3.13.
Average industry standard 1.97
17. TELADOC EFFICIENCY RATIO
Teladoc Health revenue for the twelve months ending September 30,
2022 was $2.323B, a 24.79% increase year-over-year.
Teladoc Health total assets for the quarter ending September 30,
2022 were $8.104B, a 54.09% decline year-over-year.
assets turnover ratio = revenue / total assets
the asset turnover ratio is an indicator of the efficiency with which a
company is deploying its assets. Teladoc Health asset turnover for
the three months ending September 30, 2022 was 0.08.
Average industry asset turnover ratio for the quarter ending
September 30, 2022 is 1.2
18. PFIZER PROFITABILITY RATIO
Gross profit ratio= (gross profit ÷ net sales) x100
Pfizer gross profit for the twelve months ending September 30, 2022
was $65.448B, a 45.18% increase year-over-year
Pfizer cost of goods sold for the twelve months ending September
30, 2022 was $34.431B, a 44.69% increase year-over-year
The Gross Profit Ratio of Pfizer is 73.22%
Average industry standard = 49.63%
19. PFIZER
LEVERAGE
RATIO
Dept to equity ratio = (total liabilities ÷
share holders equity )x100
Pfizer shareholder equity for the quarter
ending September 30, 2022 was $92.891B,
a 22.28% increase year-over-year
Pfizer total liabilities for the quarter ending
September 30, 2022 were $102.459B,
a 0.74% decline year-over-year
The debt/equity ratio can be defined as a
measure of a company's financial leverage
calculated by dividing its long-term debt
by stockholders' equity. Pfizer debt/equity
for the three months ending September
30, 2022 was 0.35.
Average industry standard 1.76
20. PFIZER
LIQUIDITY
RATIO
Current Ratio % = (Current Assets /
Current Liabilities) * 100
Pfizer cash on hand for the quarter
ending September 30, 2022 was $36.123B,
a 21.64% increase year-over-year
Pfizer total current liabilities for the
quarter ending September 30, 2022
were $44.314B, a 6.01% increase year-
over-year.
Current and historical current ratio for
Pfizer (PFE) from 2010 to 2022. Current
ratio can be defined as a liquidity ratio
that measures a company's ability to pay
short-term obligations. Pfizer current ratio
for the three months ending September
30, 2022 was 1.59
Average industry standard 1.97
21. PFIZER
EFFICIENCY
RATIO
Total Asset Turnover = Revenue / Total Assets
Pfizer total assets for the quarter ending
September 30, 2022 were $195.350B, a 9.02%
increase year-over-year
Pfizer revenue for the twelve months ending
September 30, 2022 was $99.879B, a 45.01%
increase year-over-year.
Current and historical asset turnover for Pfizer
(PFE) from 2010 to 2022. Asset turnover can be
defined as the amount of sales or revenues
generated per dollar of assets. The asset
turnover ratio is an indicator of the efficiency
with which a company is deploying its assets.
Pfizer asset turnover for the three months
ending September 30, 2022 was 0.12.
Average industry asset turnover ratio for the
quarter ending September 30, 2022 is 1.2
22.
23. PFIZER
OUR OUTLOOK REFLECTS THE COMPANY'S OPERATING
PROFILE, WHICH IS WELL-POSITIONED RELATIVE TO ITS
PEER AMGEN (BBB+/STABLE) IN TERMS OF SCALE,
BREADTH, DEPTH, GEOGRAPHIC REACH AND PATENT
RISK. RELATIVELY MANAGEABLE INTERMEDIATE-TERM
PATENT RISK, AN ADVANCING PIPELINE AND A BROAD
PRODUCT PORTFOLIO FURTHER SUPPORT ITS
PROSPECTS FOR OPERATIONAL AND
FINANCIAL STABILITY
THE DEFENSIBILITY OF PRICING POWER IS ALWAYS A
TOP-OF-MIND ISSUE AFFECTING THE SALES OUTLOOK
FOR PHARMACEUTICAL FIRMS, INCLUDING PFIZER. IN
ITS CURRENT FORM, THE "INFLATION REDUCTION ACT"
(IRA) THREATENS THE PROFITABILITY OF COMPANIES
THAT MANUFACTURE AND MARKET SOME OF THE TOP-
SELLING, OLDER DRUGS IN THE MEDICARE PART D
PROGRAMWHILE PFIZER HAS TWO PRODUCTS THAT
MAY BE TARGETED BY THE IRA, THE PRECISE PRODUCTS
THAT MAY BECOME SUBJECT TO PRICE NEGOTIATION
THEREUNDER REMAIN UNKNOWN. FITCH WILL
CONTINUE MONITORING DEVELOPMENTS RELATED TO
THE IRA TO BETTER ASSESS THIS RISK.
TELADOC
Teladoc (TDOC -6.50%) shined during the worst of the
of the pandemic -- and through the whole year of 2020. The
2020. The telehealth company reported massive gains in
gains in revenue and online medical visits. And the shares
the shares advanced 138%.. Teladoc's earnings reports
reports this year have been encouraging. In the
most recent quarter, for example, revenue soared 81% and
soared 81% and patient visits climbed 37% to more than
more than 3.9 million. Teladoc even increased its lowest
lowest estimate for annual revenue to $2.01 billion from
billion from the earlier estimate of $2 billion. About 60% of
billion. About 60% of consumers say they would be
be interested in a virtual healthcare plan, according to
according to Teladoc. The global telemedicine market may
market may reach more than $431 billion by 2030, an Allied
2030, an Allied Market Research report shows. That
That represents a compound annual growth rate (CAGR) of
(CAGR) of nearly 26% from this year until that point. The
point. The company aims for $2.6 billion in annual revenue
annual revenue next year. And the company is targeting $4
targeting $4 billion in revenue for 2024.
24. 1.TELADOC HEALTH REPORTS FIRST QUARTER 2019 RESULTS,
TELADOC, APRIL 30, 2019, RETRIEVED NOVEMBER 25, 2019.
2.JUMP UP TO: TELADOC ANNOUNCES CORPORATE NAME
CHANGE TO TELADOC HEALTH, BECKER'S HOSPITAL REVIEW:
ASC COMMUNICATIONS, JULY 31, 2018,
RETRIEVED NOVEMBER 17, 2019.
3.JUMP UP TO: TELADOC HEALTH ACQUIRES
MÉDECINDIRECT TO SECURE FRENCH FOOTHOLD, LES
ECHOS, MARCH 19, 2019, RETRIEVED NOVEMBER 26, 2019.
4."PFIZER INC. 2021 FORM 10-K ANNUAL REPORT" (PDF).
PFIZER.
5.WELLS, JOHN C. (2008), LONGMAN PRONUNCIATION
DICTIONARY (3RD ED.), LONGMAN, ISBN 9781405881180
6. BOMEY, NATHAN (AUGUST 25, 2020). "EXXON MOBIL,
PFIZER REMOVED FROM DOW JONES INDUSTRIAL AVERAGE;
SALESFORCE, HONEYWELL ADDED". USA TODAY.
7.STEVENS, PIPPA (AUGUST 24, 2020). "SALESFORCE, AMGEN
AND HONEYWELL ADDED TO DOW IN MAJOR SHAKE-UP TO
THE AVERAGE". CNBC
REFERENCES
